IN2014DN07888A - - Google Patents
Info
- Publication number
- IN2014DN07888A IN2014DN07888A IN7888DEN2014A IN2014DN07888A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A IN 7888DEN2014 A IN7888DEN2014 A IN 7888DEN2014A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A
- Authority
- IN
- India
- Prior art keywords
- nanostructures
- cells
- compositions
- cases
- conditions
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 7
- 239000002086 nanomaterial Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004941 influx Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 102000014452 scavenger receptors Human genes 0.000 abstract 1
- 108010078070 scavenger receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Ceramic Engineering (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601706P | 2012-02-22 | 2012-02-22 | |
| PCT/US2013/027431 WO2013126776A1 (en) | 2012-02-22 | 2013-02-22 | Nanostructures for treating cancers and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07888A true IN2014DN07888A (cs) | 2015-04-24 |
Family
ID=47833440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7888DEN2014 IN2014DN07888A (cs) | 2012-02-22 | 2013-02-22 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150064255A1 (cs) |
| EP (2) | EP3597209A1 (cs) |
| JP (1) | JP2015513543A (cs) |
| KR (1) | KR20140123597A (cs) |
| CN (1) | CN104244965A (cs) |
| AU (1) | AU2013222238A1 (cs) |
| CA (1) | CA2865279C (cs) |
| ES (1) | ES2745208T3 (cs) |
| IN (1) | IN2014DN07888A (cs) |
| MX (1) | MX2014010161A (cs) |
| WO (1) | WO2013126776A1 (cs) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100102750A (ko) | 2005-04-25 | 2010-09-24 | 메사추세츠 인스티튜트 오브 테크놀로지 | 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및 방법 |
| KR20110091019A (ko) | 2006-04-25 | 2011-08-10 | 메사추세츠 인스티튜트 오브 테크놀로지 | 오염물, 체액 또는 다른 실재물의 이동 및/또는 다른 생리학적 상태에 영향을 주기 위한 조성물 및 방법 |
| US8323686B2 (en) | 2008-04-25 | 2012-12-04 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| US9439941B2 (en) | 2009-12-14 | 2016-09-13 | The University Of Hong Kong | Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells |
| US20130034599A1 (en) | 2010-01-19 | 2013-02-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| EP2946014A2 (en) | 2013-01-17 | 2015-11-25 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3024936B1 (en) | 2013-07-25 | 2019-09-04 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
| US10220046B2 (en) | 2014-07-14 | 2019-03-05 | The Regents Of The University Of Michigan | Compositions and methods for disease treatment using nanoparticle delivered compounds |
| JP6741673B2 (ja) | 2014-10-06 | 2020-08-19 | イグジキュア, インコーポレーテッドExicure, Inc. | 抗ｔｎｆ化合物 |
| WO2016085986A1 (en) * | 2014-11-24 | 2016-06-02 | Northwestern University | High density lipoprptein nanoparticles for inflammation |
| US10307491B2 (en) | 2015-01-30 | 2019-06-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| AU2016238290B9 (en) | 2015-03-25 | 2019-06-13 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| US10967072B2 (en) | 2016-04-27 | 2021-04-06 | Northwestern University | Short interfering RNA templated lipoprotein particles (siRNA-TLP) |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS |
| MX2021008940A (es) * | 2019-01-24 | 2021-11-04 | Univ Northwestern | Nanoparticulas mimeticas de lipoproteinas de alta densidad usando andamios de nucleos conjugados con lipidos. |
| SG11202111066UA (en) * | 2019-04-26 | 2021-11-29 | Univ Northwestern | High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy |
| WO2020231860A1 (en) * | 2019-05-10 | 2020-11-19 | Northwestern University | Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses |
| KR20220066108A (ko) * | 2019-09-18 | 2022-05-23 | 노쓰웨스턴유니버시티 | 암에서 페롭토시스의 유도자로서의 고밀도 지단백질-유사 나노입자 |
| CN112569207A (zh) * | 2019-09-30 | 2021-03-30 | 复旦大学 | 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途 |
| KR102614058B1 (ko) * | 2022-06-13 | 2023-12-15 | (주) 멥스젠 | 약물전달용 재구축 고밀도 지단백 나노입자 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637678A1 (en) * | 2006-01-26 | 2007-08-09 | University Of Massachusetts | Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same |
| WO2009073984A1 (en) * | 2007-12-12 | 2009-06-18 | University Health Network | High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles |
| US8323686B2 (en) * | 2008-04-25 | 2012-12-04 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| US20130034599A1 (en) * | 2010-01-19 | 2013-02-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
-
2013
- 2013-02-22 AU AU2013222238A patent/AU2013222238A1/en not_active Abandoned
- 2013-02-22 ES ES13708044T patent/ES2745208T3/es active Active
- 2013-02-22 KR KR1020147025926A patent/KR20140123597A/ko not_active Withdrawn
- 2013-02-22 WO PCT/US2013/027431 patent/WO2013126776A1/en not_active Ceased
- 2013-02-22 US US14/380,406 patent/US20150064255A1/en not_active Abandoned
- 2013-02-22 MX MX2014010161A patent/MX2014010161A/es unknown
- 2013-02-22 EP EP19175659.2A patent/EP3597209A1/en not_active Withdrawn
- 2013-02-22 IN IN7888DEN2014 patent/IN2014DN07888A/en unknown
- 2013-02-22 CN CN201380017827.7A patent/CN104244965A/zh active Pending
- 2013-02-22 CA CA2865279A patent/CA2865279C/en active Active
- 2013-02-22 EP EP13708044.6A patent/EP2817024B1/en active Active
- 2013-02-22 JP JP2014558893A patent/JP2015513543A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2745208T3 (es) | 2020-02-28 |
| MX2014010161A (es) | 2015-03-09 |
| EP3597209A1 (en) | 2020-01-22 |
| EP2817024B1 (en) | 2019-07-10 |
| WO2013126776A1 (en) | 2013-08-29 |
| KR20140123597A (ko) | 2014-10-22 |
| CN104244965A (zh) | 2014-12-24 |
| CA2865279C (en) | 2023-04-25 |
| JP2015513543A (ja) | 2015-05-14 |
| AU2013222238A1 (en) | 2014-09-18 |
| US20150064255A1 (en) | 2015-03-05 |
| CA2865279A1 (en) | 2013-08-29 |
| EP2817024A1 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07888A (cs) | ||
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| MX2010004857A (es) | Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel. | |
| PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| CA2865011C (en) | Methods and compositions for treating huntington's disease | |
| NZ709215A (en) | Compositions comprising anti-cd38 antibodies and lenalidomide | |
| WO2010132697A3 (en) | Methods and compositions for treatment | |
| NZ715201A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| PH12012502380B1 (en) | Methods of treatment of pancreatic cancer | |
| SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
| GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
| EP3587558A3 (en) | Methods of populating a gastrointestinal tract | |
| PH12015500879A1 (en) | Compositions and methods for treating proteinopathies | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| MX2015001250A (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| MX394137B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
| GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| WO2012170947A3 (en) | Methods for modulating factor 12 expression | |
| DK2714888T3 (da) | Rekombinant gær | |
| IN2014CN03610A (cs) | ||
| MX359210B (es) | Composición de combinación de pac-1 y tamoxifeno. | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX366380B (es) | Composiciones prebioticas para el cuidado oral que contienen un alquilglucosido. |